CAS NO: | 1229194-11-9 |
规格: | ≥98% |
包装 | 价格(元) |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
1g | 电议 |
Molecular Weight (MW) | 738.27 |
---|---|
Formula | C24H30ClN7O4S.C7H8O3S.H2O |
CAS No. | 1229194-11-9 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 100 mg/mL (135.5 mM) |
Water: <1 mg/mL | |
Ethanol: <1 mg/mL | |
SMILES Code | O=C(NC1=NC=C(Cl)C=C1)C(N[C@@H]2[C@H](NC(C(S3)=NC4=C3CN(C)CC4)=O)C[C@@H](C(N(C)C)=O)CC2)=O.CC5=CC=C(S(=O)(O)=O)C=C5.[H]O[H] |
Synonyms | DU176b; DU 176b; Edoxaban; DU-176; DU 176; DU-176b; DU176; Edoxaban tosylate monohydrate, trade name Lixiana. |
In Vitro | In vitro activity: In human plasma, Edoxaban doubles prothrombin time and activates partial thromboplastin time at 0.256 and 0.508 μM, respectively. Cell Assay: Edoxaban tosylate monohydrate (DU-176b) inhibited FXa with Ki values of 0.561 nM for free FXa, 2.98 nM for prothrombinase, and exhibited>10 000-fold selectivity for FXa. DU-176b doubled prothrombin time and activated partial thromboplastin time in human plasma. DU-176b did not impair platelet aggregation by ADP, collagen or U46619 . |
---|---|
In Vivo | Oral administration of Edoxaban produces potent anti-Xa activity and high drug concentration in plasma in rats and monkeys. In vivo, Edoxaban dose-dependently inhibits thrombus formation in rat and rabbit thrombosis models. |
Animal model | Venous stasis thrombosis model in rats and rabbits |
Formulation & Dosage | Dissolved in 0.5% methylcellulose; 0.3–3 mg/kg (Rabbit); 0.5–12.5 mg/kg (Rat); oral gavage |
References | J Thromb Haemost. 2008 Sep;6(9):1542-9. |